Skip to main content

Marc Rivas Agudo

Institutions of which they are part

Diabetes and Metabolism
Vall Hebron Institut de Recerca

Marc Rivas Agudo

Institutions of which they are part

Diabetes and Metabolism
Vall Hebron Institut de Recerca

Projects

Diabetis i metabolisme

IP: Rafael Simó Canonge
Collaborators: Josep A Villena Delgado, Carles Zafon Llopis, Cristina Hernández Pascual, David Martinez Selva, Rosario Pardo Diaz, Angel Michael Ortiz Zúñiga, Andreea Ciudin Mihai, Fiorella Ximena Palmas Candia, Ana Maria Ortiz de Urbina Olive, Monica Sanchez Bartres, Lorena Ramos Pérez, Marc Rivas Agudo, Diabetis i metabolisme, Anna Casteras Román, Alejandra Planas Vilaseca, Betina Biagetti Biagetti, Judit Amigó Farran, Mercè Abad Martín, Marta Comas Martínez, Hugo Ramos Abellan, Rosa Burgos Peláez, David Sabater Martínez, Olga Simó Servat, Patricia Bogdanov Baruj, Maria Llorian Salvador, Enzamaría Fidilio Meli
Funding agency: Agència Gestió Ajuts Universitaris i de Recerca
Funding: 60000
Reference: 2021 SGR 00655
Duration: 01/01/2022 - 30/06/2025

Estudio de seguridad y eficacia de la sitagliptina en colirio para el tratamiento de los estadios iniciales de retinopatía diabética.

IP: Rafael Simó Canonge
Collaborators: Marc Rivas Agudo, Cristina Hernández Pascual, José García Arumí
Funding agency: Instituto de Salud Carlos III
Funding: 573650
Reference: ICI20/00129
Duration: 01/01/2021 - 31/10/2026

Incidència de complicacions de l'accés venós perifèric en la població diabètica tipus 2. Anàlisi dels factors de risc i estudi comparatiu de dos dispositius perifèrics.

IP: Rafael Simó Canonge
Collaborators: Marc Rivas Agudo, Miriam Izquierdo Sans
Funding agency: Generalitat de Catalunya - Departament de Salut
Funding: 73343.84
Reference: SLT008/18/00104
Duration: 01/07/2019 - 20/03/2021

Related news

The work represents a paradigm shift in the clinical approach to this chronic, multifactorial disease, based on the clinical context of each patient and not only on weight loss.

The results of a phase 3 clinical trial show that orforglipron reduces body weight by an average of 11% and improves cardiovascular risk factors.

Dr. Maria Llorián-Salvador, from the Diabetes and Metabolism Research Group at VHIR, is leading this project to identify new therapies for this inherited disease that causes progressive vision loss.

Related professionals

María Luisa Paños Gonzalo

María Luisa Paños Gonzalo

Reconstructive Surgery of the Locomotor System
Read more
Jorge Pérez López

Jorge Pérez López

Genetics Medicine
Read more
Marta Sanchiz Cruz

Marta Sanchiz Cruz

Research technician
Infectious Diseases
Read more
M. Mercè Fabregat  Bosch

M. Mercè Fabregat Bosch

Reconstructive Surgery of the Locomotor System
Read more

Subscribe to our newsletters and be part of the Campus life

We are a world-leading healthcare complex where healthcare, research, teaching and innovation go hand in hand.

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.